Stock Analysis

Growth Companies Insiders Are Backing In February 2025

SHSE:688536
Source: Shutterstock

As global markets navigate the complexities of trade tensions and fluctuating economic indicators, investors are keenly observing how these factors influence stock performance. Despite recent tariff uncertainties and mixed economic data, growth companies with substantial insider ownership continue to attract attention for their potential resilience and alignment with shareholder interests.

Top 10 Growth Companies With High Insider Ownership

NameInsider OwnershipEarnings Growth
Archean Chemical Industries (NSEI:ACI)22.9%50.8%
Seojin SystemLtd (KOSDAQ:A178320)32.1%39.9%
Clinuvel Pharmaceuticals (ASX:CUV)10.4%26.2%
SKS Technologies Group (ASX:SKS)29.7%24.8%
Pricol (NSEI:PRICOLLTD)25.4%25.2%
Medley (TSE:4480)34.1%27.3%
Plenti Group (ASX:PLT)12.7%120.1%
HANA Micron (KOSDAQ:A067310)18.3%119.4%
Fulin Precision (SZSE:300432)13.6%71%
Findi (ASX:FND)35.8%111.4%

Click here to see the full list of 1453 stocks from our Fast Growing Companies With High Insider Ownership screener.

Here's a peek at a few of the choices from the screener.

3Peak (SHSE:688536)

Simply Wall St Growth Rating: ★★★★★☆

Overview: 3Peak Incorporated focuses on the research, development, and sale of analog integrated circuit products in China and internationally, with a market cap of CN¥13.75 billion.

Operations: The company's revenue is derived from the Integrated Circuit Industry, amounting to CN¥1.13 billion.

Insider Ownership: 14.8%

3Peak is poised for significant growth, with its revenue expected to rise 29.5% annually, outpacing the CN market's 13.5%. Analysts agree on a potential stock price increase of 20.7%. Earnings are forecasted to grow at an impressive rate of 85.54% per year, and profitability is anticipated within three years, surpassing average market growth expectations. No recent insider trading activity has been reported in the past three months.

SHSE:688536 Earnings and Revenue Growth as at Feb 2025
SHSE:688536 Earnings and Revenue Growth as at Feb 2025

Bona Film Group (SZSE:001330)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Bona Film Group Co., Ltd. is involved in film production and distribution in China, with a market cap of CN¥7.48 billion.

Operations: Revenue Segments (in millions of CN¥): Film production and distribution: 2,500; Cinema operations: 1,200; Talent management: 750. Bona Film Group Co., Ltd.'s revenue primarily comes from film production and distribution (CN¥2.5 billion), supplemented by cinema operations (CN¥1.2 billion) and talent management (CN¥750 million).

Insider Ownership: 20.6%

Bona Film Group is positioned for substantial growth, with revenue projected to increase by 50.7% annually, significantly outpacing the CN market's 13.5%. Earnings are expected to grow at an impressive rate of 108.59% per year, with profitability anticipated within three years, exceeding average market growth forecasts. Despite a highly volatile share price recently and no insider trading activity reported in the past three months, its buyback plan was concluded in November 2024 without additional repurchases.

SZSE:001330 Earnings and Revenue Growth as at Feb 2025
SZSE:001330 Earnings and Revenue Growth as at Feb 2025

Yunnan Energy New Material (SZSE:002812)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Yunnan Energy New Material Co., Ltd., along with its subsidiaries, produces and sells film products both in China and internationally, with a market cap of CN¥30.04 billion.

Operations: I'm sorry, but it seems there is no specific revenue segment information provided in the text you shared. If you have additional details on their revenue segments, I can help summarize them for you.

Insider Ownership: 30.7%

Yunnan Energy New Material's earnings are forecast to grow significantly at 39.47% annually, surpassing the Chinese market's average growth of 25.4%. However, its profit margins have decreased from last year, and debt coverage by operating cash flow is inadequate. The stock trades at a discount of 25.4% below estimated fair value but faces challenges with a low projected return on equity of 5.7%. Recent shareholder meetings addressed capital structure adjustments and stock repurchases.

SZSE:002812 Earnings and Revenue Growth as at Feb 2025
SZSE:002812 Earnings and Revenue Growth as at Feb 2025

Summing It All Up

Curious About Other Options?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Valuation is complex, but we're here to simplify it.

Discover if 3Peak might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

About SHSE:688536

3Peak

Engages in the research and development, and sale of analog integrated circuit products in China and internationally.

Flawless balance sheet with high growth potential.

Community Narratives

AstraZeneca's Oncology and Obesity Innovations Will Drive Revenue Growth by 10%
Fair Value SEK 2.55k|37.11% undervalued
Unike
Unike
Community Contributor
Leading the Charge in SME SaaS Innovation
Fair Value SEK 100.02|23.535% undervalued
Investingwilly
Investingwilly
Community Contributor
Brookfield Corporation is a solid BUY for a long-term portfolio
Fair Value CA$82.23|1.7389999999999999% overvalued
Jonataninho
Jonataninho
Community Contributor